HC Wainwright Has Bearish Estimate for NBIX Q1 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, April 22nd. HC Wainwright analyst A. Fein now expects that the company will earn ($0.25) per share for the quarter, down from their prior forecast of $0.11. HC Wainwright has a “Buy” rating and a $168.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $1.11 EPS, Q4 2025 earnings at $1.34 EPS, FY2025 earnings at $2.79 EPS and FY2028 earnings at $10.82 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

A number of other research firms have also weighed in on NBIX. Canaccord Genuity Group dropped their price objective on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada raised shares of Neurocrine Biosciences from a “sector perform” rating to an “outperform” rating and cut their price objective for the company from $138.00 to $137.00 in a report on Monday, April 14th. Guggenheim reduced their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Wedbush dropped their target price on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $161.14.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $105.76 on Thursday. The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 0.77 and a beta of 0.33. The company’s fifty day moving average price is $107.30 and its 200-day moving average price is $122.12. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $157.98.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Golden State Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $25,000. Huntington National Bank grew its holdings in Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after acquiring an additional 97 shares in the last quarter. Brooklyn Investment Group increased its position in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares during the period. GeoWealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after purchasing an additional 102 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its position in shares of Neurocrine Biosciences by 53.5% in the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after purchasing an additional 130 shares during the period. 92.59% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the transaction, the director now owns 517,030 shares of the company’s stock, valued at $79,064,227.60. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Julie Cooke sold 1,551 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the completion of the sale, the insider now directly owns 19,544 shares of the company’s stock, valued at approximately $2,282,348.32. This trade represents a 7.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 167,906 shares of company stock valued at $24,671,530. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences declared that its Board of Directors has approved a share repurchase program on Friday, February 21st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.